Elsevier

Clinical Lung Cancer

Volume 8, Issue 6, May 2007, Pages 382-385
Clinical Lung Cancer

Original Contribution
A Phase II Study of Single-Agent Oral Vinorelbine in Patients with Pretreated Advanced Non–Small-Cell Lung Cancer

https://doi.org/10.3816/CLC.2007.n.019Get rights and content

Abstract

Purpose

Intravenous vinorelbine has demonstrated its efficacy and tolerability in advanced non–small-cell lung cancer (NSCLC). An oral formulation of vinorelbine has been developed, and a number of phase II studies have shown its activity in chemotherapy-naive NSCLC, even in elderly patients, but no study has been performed to test activity and toxicity of oral vinorelbine in pretreated patients. The aims of our study were to investigate the activity and toxicity of oral vinorelbine in patients with NSCLC as salvage treatment.

Patients and Methods

Twenty pretreated patients with locally advanced (n = 6) and metastatic (n = 14) NSCLC entered the study. The schedule was oral vinorelbine 60 mg/m2 once a week until progression or development of unacceptable toxicity. Median age was 70 years (range, 49–84 years).

Results

Seventeen patients were evaluable for response and all for toxicity. A median of 9 cycles were administered (range, 2–21 cycles). No objective responses were reported, 5 patients experienced stable disease, and 12 patients had progressive disease. Median time to progression was 2 months (range, 1–6 months), and median survival was 4 months (range, 1–13 months). Treatment was well tolerated, with grade 4 neutropenia in 1 patient (heavily pretreated); grade 2 diarrhea in 2 patients; asthenia in 2 patients; and abdominal pain in 1 patient.

Conclusion

Oral vinorelbine 60 mg/m2 once a week is a very safe schedule in heavily pretreated locally advanced and metastatic NSCLC; however, at this dose, the drug is inactive. Other phase II studies with oral vinorelbine 80 mg/m2 weekly are warranted.

References (17)

There are more references available in the full text version of this article.

Cited by (0)

Electronic forwarding or copying is a violation of US and International Copyright Laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

View full text